Fremanezumab in Children and Adolescents with Episodic Migraine

New England Journal of Medicine 2026

View at publisher
Authors: Andrew D. Hershey, Christina L. Szperka, Piero Barbanti, Patricia Pozo-Rosich, Petra Bittigau, Steve Barash, Juline Bryson, Yoel Kessler, Yael Carmeli Schwartz, Verena Ramirez Campos, Xiaoping Ning
DOI: 10.1056/nejmoa2504546
Cited by: 21
References: 29

Abstract

BACKGROUND: Fremanezumab, a humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, is approved for the prevention of migraine in adults. Evidence from randomized, controlled trials in children and adolescents is needed. METHODS: We randomly assigned participants 6 to 17 years of age with a diagnosis of episodic migraine (defined as migraine for ≥6 months and a history of ≤14 headache days per month) to receive monthly subcutaneous injections of fremanezumab (120 mg for participants with a body weight of

Fields of Study & Subjects

Migraine and Headache Studies Neurological Complications and Syndromes Vestibular and auditory disorders

Publication details

Journal / source
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Volume
394
Issue
3
Pages
243–252
Publication date
14 January 2026
Language
EN